Compare Novartis AG (NVS) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Novartis AG trades at $143.11 (market cap $268.57B), while Direxion Daily FTSE China Bull 3x Shares trades at $24.52 (market cap $560.32M). The key difference: Novartis AG is far larger — about 479.3× Direxion Daily FTSE China Bull 3x Shares's market cap, and Novartis AG pays a 3.31% dividend while Direxion Daily FTSE China Bull 3x Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| NVS | YINN | |
|---|---|---|
Market Cap | $268.57B | $560.32M |
Volume | 1,532,573 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $168.62 | $52.69 |
52-Week Low | $121.80 | $21.45 |
Typical Hold Time | 82 Days | 25 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
YINN is trading at $23.56, down 2.97% with bearish technical indicators showing 18 sell signals versus 1 buy. The stock faces resistance at $24 with support at $23. Recent corporate actions include a $0.56 dividend scheduled for September 2026. Technical analysis indicates strong bearish momentum with moving averages unanimously negative.
The outlook remains challenging with bearish technical positioning and limited fundamental data availability. Key risks include market volatility and sector-specific headwinds. Investment opportunities may emerge if the stock stabilizes above support levels, but current momentum suggests continued downward pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
